Navigation Links
Drop in breast cancer rates directly tied to reduced hormone therapy
Date:11/30/2010

In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.

The declines occurred in the age groups that most widely embraced then abandoned hormone therapy.

For nearly a decade, postmenopausal women have been strongly advised to refrain from long-term hormone therapy or to use the lowest dose possible for the shortest time to relieve hot flashes and night sweats. Numerous studies have suggested that women taking a combination of progestin and estrogen faced a higher risk of breast cancer and other potential health hazards.

The new findings suggest that hormones helped promote breast tumor growth of preexisting, clinically latent hormone-dependent cancers, not only increasing the incidents of invasive cancer, but also the risk of ductal carcinoma in situ (DCIS).

"We show that the incidence of breast cancer decreases if you take the hormones away,'' said senior author Karla Kerlikowske, MD. "The fact that we're continuing to see a decrease in invasive cancer means that the effects of stopping the hormones may be long-lasting.''

The study has been published online by the "Journal of Clinical Oncology.'' http://jco.ascopubs.org/content/early/2010/11/08/JCO.2010.29.5121.full.pdf+html?sid=b3f9dc48-1229-4ad7-877f-51e633bf1453

The use of hormone therapy surged in the 1980s and '90s an estimated six million American women found that the medications alleviated postmenopausal symptoms. But at the same time, there was a steady increase in the rate of breast cancer.

In mid-2002, following a landmark report of the Women's Health Initiative indicating that the risks of estrogen plus progestin therapy outweighed its benefits, hormone therapy fell into widespread disfavor. Women by the millions gave up hormones cold turkey or incrementally.

In the new UCSF study, scientists reviewed 2,071,814 screening mammography examinations performed between January 1997 and December 2008 on nearly 700,000 women between the ages of 40 and 79 as part of routine regular screening mammography.

They uncovered a clear pattern: women 50 to 69 years old had the highest level of hormone usage and showed the biggest reduction in invasive breast cancer when they stopped, from 40 cancers per 10,000 mammograms in 2002 to 31 cases in 2005, 35 cancers in 2006. Likewise, rates of DCIS markedly dropped in the same age group after hormone therapy ended.

There was a parallel drop in cancer among women older than age 70.

Strikingly, the scientists found that among women 40 to 49 years old, who were less likely to have been on hormone therapy, breast cancer rates did not change over the course of the decade studied.

The results corroborate previous declines in invasive cancer between 2000 and 2003 reported for women aged 50 to 69 by the same group of scientists as well as other researchers. To the authors, the statistics offer convincing evidence that hormone therapy cessation reduces breast cancer risk.

The scientists say major questions remain unanswered: does a halt in hormone therapy correlate to a delay in the clinical detection of tumors, leading to a short-term reduction in cancer rates, but not a long-term drop? Do the effects apply long term for all tumors influenced by hormone therapy?

"The study supports the idea that by giving the hormones we were promoting tumor growths by giving the hormones,'' said Kerlikowske, professor of medicine, and epidemiology and biostatistics at the UCSF Helen Diller Family Comprehensive Cancer Center, and co-director of the Women Veteran's Comprehensive Health Center at SFVAMC. "When the promoter is taken away, the incidence of breast cancer decreases.''

While scientists continue to investigate the relationship between hormones and cancer, Kerlikowske said that using hormone therapy on a short term basis is "probably OK. But long term, it is not OK.''


'/>"/>

Contact: Elizabeth Fernandez
EFernandez@pubaff.ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Sporadic breast cancers start with ineffective DNA repair systems, Pitt researchers find
2. Women With Breast Cancer History Should Consider MRI: Study
3. Women with personal history of breast cancer should be screened with MRI
4. Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
5. Discovery halts breast cancer stem cells
6. Targeted breast ultrasound plays key role in evaluating breast abnormalities in women younger than 40
7. Cough Syrup Might Help With Dosing of Breast Cancer Drug
8. I-SPY 2 study speeds up treatment for breast cancer
9. Cough medicine could help doctors identify how breast cancer patients metabolize tamoxifen
10. Scientists identify potential new target for treating triple negative breast cancer
11. Erythropoietin counteracts breast cancer treatment with herceptin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated ... National Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual ... Bunkum winner is the Center for American Progress (CAP), for its report, Lessons From ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
Breaking Medicine Technology: